Stance: Divergent (value chain segments and isotope types run hot and cold) | Observation horizon: 12–24 months | Report date: 2026-11-16
One-sentence conclusion: The structural uptrend in therapeutic isotope demand driven by radioligand therapy (RLT) is a real story — Lu-177 global treatment courses have a central growth rate of about 15% over the next five years, and Ac-225 is on the eve of a magnitude leap as approvals near; but the supply side is simultaneously staging a capacity arms race: Mo-99 will shift from tight balance to structural oversupply in 2028–2029, the Lu-177 feedstock's tight balance will gradually loosen over 2026–2028, and Ac-225 is the only isotope whose scarcity premium can persist for another 2–4 years. The segments that keep making money are not in feedstock, but at two ends: the branded drug closed loop (the Novartis-style self-built production lines + administration networks) and licensed distribution networks. Going long on midstream feedstock capacity on the logic of "isotope scarcity" will most likely mean buying right before a concentrated release of supply.
This report covers the full chain of medical isotopes and radiopharmaceutical distribution networks: isotope production (reactor irradiation / accelerators) → hot-cell purification and separation → GMP quality release → radioactive cold-chain distribution → radiopharmacy networks / in-hospital administration. The research is broken down by isotope: diagnostics — Mo-99/Tc-99m (SPECT base), F-18/Ga-68 (PET); therapeutics — Lu-177, Ac-225, I-131, Y-90, Ra-223. Radiopharmaceutical innovation pipelines (RDC/RLT) are treated only as demand context and are not repeated in the oncology innovative drug overview. The distribution network covers the US nuclear pharmacy systems of Cardinal Health, Jubilant, and PharmaLogic, and the radiopharmacy station systems of China Isotope & Radiation Corporation (CIRC), Atomic Hi-Tech (a CIRC subsidiary), and Dongcheng Pharmaceutical. This industry is analyzed on a generic value chain basis; there is no corresponding SW industry classification index on A-shares, so valuation discussion is presented via individual stock valuation anchors (see I5).
One-sentence value chain map: a handful of aging research reactors and new accelerators produce isotope feedstock → hot-cell processors purify it into GMP-grade API → branded drugmakers such as Novartis synthesize finished products and control their own distribution (or outsource to third-party nuclear pharmacies) → half-life determines distribution radius and network density → hospital nuclear medicine departments administer, settled via medical insurance or self-pay.
Isotope-by-isotope demand base (2025 base year):
| Isotope | Annual global demand (basis) | Use mix | Central growth rate | Key sources |
|---|---|---|---|---|
| Mo-99/Tc-99m | ~9,600 six-day Ci/week (converted from NEA 2025 basis of 18,500 six-day TBq/year) | Diagnostics (bone/cardiac/renal, ~80% of nuclear medicine procedure volume) | Developed markets ~+0.5%/yr; China SPECT ~+2% | OECD NEA, WNA |
| Lu-177 | ~19,900 treatment courses/yr, delivering ~754 TBq (~20.4 kCi) | Therapeutics: Pluvicto USD 1.994 bn (+43%), Lutathera USD 816 mn (+13%) | Courses 2025–2030 CAGR ~15% (this report's base case; range 13–18%) | Novartis FY2025 results |
| Ac-225 | ~3,000 clinical courses/delivering ~2.4 Ci (under DOE allocation) | Therapeutics: mainly clinical trials | Low base, approval-driven leap | DOE Isotope Program |
| F-18 | China PET(/CT) 1.382 mn scans (2023, +62.6% over four years) | Diagnostics (FDG/PSMA-18F) | China CAGR ~12.9%; US steady growth | Chinese Society of Nuclear Medicine 2024 national survey |
| Ga-68 | ~20,000 imaging scans in China (early penetration) | Diagnostics (PSMA/SSTR) | Low base, high growth | Same as above |
| I-131 | ~198,000 procedure instances/yr in China (hyperthyroidism + thyroid cancer) | Therapeutics | ~+2% | Same as above |
| Y-90 | SIRT tens of thousands of doses/yr | Therapeutics (liver cancer) | Grand Pharma nuclear medicine anti-tumor segment FY2025 ~HKD 950 mn, +61% YoY (company basis, cited secondhand) | Grand Pharma FY2025 results |
The structural core of demand is the forward migration of the RLT treatment line: Pluvicto received FDA approval for the mHSPC first-line indication on 2026-07-31 (PSMAddition, Phase III rPFS HR 0.72), expanding the treatable population pool by roughly 3–4x in one step (inferred layer); combined with China's dual-indication approval in 2025-11 (brand name 派威妥/Pluvicto), demand is diffusing from late-line in Europe and the US toward first-line globally. Novartis's combined RLT revenue in FY2025 was USD 2.81 bn (+33%), with Pluvicto alone at USD 1.29 bn (+57%) in 1H2026. A discipline note on basis is warranted: the treatment course count is an estimate based on a net price of ~USD 160,000 per course (Novartis only discloses sales, not courses; the implied discount between the WAC list price of USD 42,500/dose and the estimated net price is rather large, so the course count is for magnitude reference only), and all monetary-layer conclusions should rely strictly on company-disclosed sales.
Demand bridge (base scenario): 19,900 courses in 2025 → mCRPC existing indication volume +7,500, mHSPC first-line +8,000 (8% penetration assumption, range 5,000–12,000, corresponding to 5–12% penetration), China volume +5,000, Lutathera/NET +1,500 (halved after erosion by the BRAVNETSA generic, FDA final approval on 2026-09-22), new pipeline risk-adjusted +3,000, competition and slower-than-expected penetration -5,000 → 2030E ~39,900 courses (range 37,000–45,000), corresponding to delivery of ~1,550–1,770 TBq. Ac-225 demand bridge: 3,000 → RYZ101 (BMS, positive ACTION-1 Phase III interim results, 2026-10-12) +15,000, FPI-2265 (AstraZeneca–Fusion) +12,000, other α pipelines net +3,000 → 2030E ~33,000 courses, delivering ~27 Ci, with production-basis demand of ~80 Ci. Structural vs. steady-state: therapeutic isotopes (Lu/Ac) and PET imaging are structural growth; Tc-99m diagnostics has peaked in developed markets (+0.5%/yr) and is being slowly eroded by PET, with China as the last source of mid-single-digit incremental growth; I-131 is steady-state. Demand has almost no macro cyclicality, but exhibits step-function pulses of "approval — reimbursement — distribution center certification."
Mo-99: the Big Four's aging-reactor landscape + two new capacity streams, US and China. In-production capacity is highly concentrated: ANSTO, IRE, Curium, and NTP account for ~95% of global supply (NASEM/Euratom basis); the main reactors (BR2/HFR/Maria/LVR-15/SAFARI-1/OPAL) are mostly aging units built in the 1960s–70s, with nameplate capacity habitually ~50% above demand to compensate for decay losses, idle in the form of planned maintenance and spare target positions; the 2024 HFR cooling-water leak and 9-month outage once caused regional shortages of 50–100%, exposing single-point fragility. Key new variables: ① SHINE (US, D-T neutron source + LEU solution subcritical fission) — as of 2026-04 the facility is ~75% complete, the NRC completion deadline has been extended to 2029-12-31, and it has secured a DOE conditional loan of up to USD 263 mn; per company statements, Phase I will be "essentially complete and in commercial production in 2027," and full capacity of 8,200 six-day Ci/week ≈ 85% of global weekly demand (ANS) — but the operating license is not yet approved, making timing one of the industry's biggest uncertainties; ② the CNNC Nuclear Power Institute of China's Sichuan medical isotope solution reactor — construction began 2024-01, 42-month schedule, company statements targeting completion and commissioning in 2027; designed for 100,000 Ci/yr Mo-99 + 20,000 Ci/yr I-131, with SASAC explicitly stating it "exceeds current domestic demand"; its role is first and foremost import substitution, with marginal impact on the global balance after 2028; ③ Darlington (Canada, BWXT / commercial co-irradiation) in production since 2024. Cautionary precedent: NorthStar (non-uranium activation route) shut down its Mo-99 line in 2023-12 and pivoted to Ac-225 — nameplate capacity does not equal economic capacity.
Lu-177: from single dominance to multi-point diffusion. n.c.a. Lu-177 is currently dominated by ITM (whose NOVA plant in Munich started up in 2024, and which has been Novartis's long-term supplier since 2020), with ANSTO, Eckert & Ziegler, and MURR (global direct sales since 2026-03) following; c.a. Lu-177 from Russia's Rosatom is said to account for ~30% of global formulations. The expansion pipeline is dense: ITM's Neufahrn expansion (EUR 188 mn raised in 2024), Bruce Power U7 hot cells completed 2026-07 / Canadian approval 2026-08, China's Qinshan commercial heavy-water reactors supplying commercial Lu-177 to market since 2025-06, 8 production lines at the Jiajiang base activated 2025-01, and existing n.c.a. lines at CAEP/NPIC — China is shifting from ~95% import dependence toward self-sufficiency and evolving into an exporter. Ac-225: the only genuinely scarce segment. The legacy route (DOE Tri-lab, Th-229 stockpile) historically supplied only single-digit Ci per year, and the 2027 supply year remains application-allocation based; commercial routes are ramping — TerraPower Isotopes began commercial-scale production in 2024-10, broke ground on a new Philadelphia plant in 2026-05 (commissioning 2029, ~20x capacity increase), NorthStar's accelerator route reached weekly production by end-2025 (single unit designed at 200 Ci/yr), EZAG–ÚJV switched to continuous production in 2026-02, and Niowave's new plant will be completed in 2028; academic estimates suggest global nameplate capacity could exceed 25 TBq (~676 Ci) by 2032. Quality certification and distribution radius (determined by half-life physics): purified → pharmacopoeial (USP/EP/ChP) release requires 2–6 hours of QC per batch — a hard bottleneck for short-half-life isotopes; Tc-99m (6.0h) relies on weekly Mo-99 generator supply + daily in-hospital elution; F-18 (110min) is limited to same-day delivery within a 30–50km in-hospital/regional cyclotron radius; Ga-68 (68min) uses Ge-68 generators (271 days) or direct cyclotron production; Lu-177 (6.7 days) allows centralized synthesis + 3–7 day global cold chain; Ac-225 (9.9 days) is reachable transoceanically; Y-90 (64h) has a same-day/next-day radius; I-131 (8 days) allows nationwide distribution — distribution radius = network density = licensing barrier. The US nuclear pharmacy network is largest at Cardinal Health with ~130 pharmacies + 30 PET sites; China is a duopoly of CIRC + Dongcheng (combined 2025 radiopharmaceutical revenue of RMB 6.74 bn).
Mo-99 balance (six-day Ci/week, deliverable basis): tight balance in 2025–2026 (deliverable surplus of ~+3% to +7%, sustained by maintenance redundancy); from 2027 the direction hinges on SHINE — base case (adopted by this report; SHINE delay probability ≥60%): operating license and ramp-up lag; 2027 remains tight (+6%), shifting to oversupply in 2028–2029 (+23% to +37%); on-schedule SHINE case: oversupply as early as 2H2027 at +38%, 2028 at +70%. The hedging variable is the aging reactors: HFR is slated to run until PALLAS takes over in 2032 (NucNet), but unplanned outages at 1960s-era reactors (the 2024 HFR precedent) and LVR-15's approaching end of life are permanent tail risks.
Lu-177 balance (production basis TBq/yr = delivery × 2.5 decay multiplier): tight balance in 2025 (+0.8%); as the demand base case moderates (CAGR ~15%) and ITM/Bruce/China capacity comes online, it loosens in 2026 (+11%), 2027 +20%, 2028 +29% — the end of tight balance comes earlier and more gradually than Mo-99's; a downward shift in the price center is a trend, not a risk event. Ac-225: 2025 gap of ~-56% (allocation regime is the proof); 2026–2027 turns to balance as commercial capacity ramps (nameplate 25–70 Ci vs. demand of 18–35 Ci); 2028–2029 nameplate loosens, but GMP-release capacity (single-digit to low-double-digit Ci) lags nameplate capacity significantly (the NorthStar precedent); the scarcity premium window most likely persists until 2029–2030, after which nameplate capacity (676 Ci) is ~8x 2030 demand (80 Ci) and the direction reverses.
Pricing mechanism and 12-month base-case price path: this industry has no exchange-traded prices — Mo-99 is locked-volume, locked-price long-term contracts between the Big Four and generator makers (NEA's longstanding conclusion: current prices are insufficient to cover full costs + reserve capacity; price elasticity comes from outage pulses, not demand); Lu-177 feedstock is ITM–Novartis-style multi-year contracts plus spot inquiries; back-solving from "feedstock at 1–2% of finished drug price" gives n.c.a. ~USD 57–115/GBq (inferred band); Ac-225 is DOE allocation inquiries + commercial contracts, with research-grade historical magnitudes of ~USD 1.0–1.5 mn/Ci. Policy anchor: from US Medicare CY2026, OPPS pays for radiopharmaceuticals at ASP+6%, plus an extra USD 10 per dose for Tc-99m from domestically produced Mo-99 sources (a targeted supply-side subsidy, limited in magnitude). Base-case path: Mo-99 contract prices flat over the next 12 months (0 to +5%, depending on aging-reactor maintenance and SHINE licensing progress; if SHINE shipments move earlier, -5% to -12%); Lu-177 n.c.a. center -10% to -25% (BRAVNETSA generic launch + capacity release; c.a. declines less due to Russian material and Yb-176 target constraints); Ac-225 premium of 0 to +15% sustained through 2027, retreating after 2029–2030.
Concentration: Mo-99 — the Big Four hold ~95% (homogeneous commodity; further commoditized after HALEU conversion); n.c.a. Lu-177 — nominally multiple players but commercial-grade capacity remains highly concentrated at ITM (acquired by Telix for $1.65 billion upfront + $700 million contingent consideration in September 2026); Ac-225 — only 6-7 companies globally in production or construction (DOE system, TerraPower, EZAG, ITM, NorthStar, Nusano); US nuclear pharmacies: Cardinal (~130 sites) > Jubilant > PharmaLogic; China: China Isotope & Radiation + Dongcheng Pharma duopoly.
Profit pool stratification (this report's core judgment): ①Branded pharma side takes the lion's share — Novartis RLT revenue of $2.81 billion in 2025; big pharma patented drugs carry 80%+ gross margins. In the Pluvicto value chain, Lu-177 raw material accounts for only ~1-2% of the finished product price (the global n.c.a. Lu-177 market is roughly $160-200 million, less than 10% of Pluvicto's standalone revenue); synthesis/QC/distribution profits are internalized through Novartis' four self-built plants (Millburn/Indianapolis/Carlsbad/Ivrea) and 700+ trained administration centers — third-party nuclear pharmacy networks largely miss out on the therapeutic dividends of flagship RLTs; their cash-cow components are Tc generators and the PET diagnostics business (Cardinal NPHS FY2025 revenue of $1.578 billion, +15.3%; cumulative goodwill impairments of $829 million highlight lessons from its M&A history, FY25 annual report). ②Scarce APIs command strong temporary bargaining power — ITM's 2025 revenue of $273 million, profitable, 40% four-year CAGR; its $1.65 billion acquisition price confirms the premium capital markets assign to scarce upstream capacity. But this premium is tied to scarcity itself and will fade as capacity comes online 2027-2030. ③Licensed distribution networks are steady cash cows — China Isotope & Radiation's nuclear medicine segment posted 2025 revenue of RMB 4.02 billion at ~70% gross margin (segment gross profit RMB 2.82 billion / revenue RMB 4.02 billion); US Cardinal NPHS growing at double digits. ④Commodity-grade Mo-99 APIs have the thinnest margins, facing volume-price pressure once new capacity (SHINE/Chinese reactors) comes online. Profit pool migration direction (2-3 years): from branded players toward upstream scarce APIs (Ac-225 long-term contracts/self-build) and downstream administration networks at both ends — but branded players dominate vertical integration via "self-build + M&A," with cumulative M&A spending exceeding $15 billion in 2023-2026: Lilly-Point $1.4 billion, BMS-RayzeBio $4.1 billion, AstraZeneca-Fusion $2.4 billion, Novartis-Mariana $1.0 billion upfront, Lantheus-LMI $350 million + Evergreen $250 million, Curium-merger with Lantheus up to $8 billion, Telix-ITM $1.65 billion.
Return quality conclusion: This business overall is "moderately attractive but severely stratified." The truly profitable segments = branded closed loops (patents + pricing power + internalized distribution), licensed distribution networks (licenses + delivery radius + hospital lock-in; high and sustainable cash flows), and scarce APIs within a short window (Ac-225 through 2029-2030). The grow-revenue-without-profit risk segments = commodity-grade Mo-99 (CR4 at 95% but homogeneous price competition), Ac-225 new capacity with concentrated commissioning in 2028-2030 (nominal capacity = several times demand), and second-tier RDC pipeline companies without isotope supply or network lock-in (PNT2002's "positive SPLASH Phase III yet no registration push" has set the precedent). Valuation positioning: SW (Shenwan) has no "medical isotope/radiopharmaceutical" industry index, so industry-level valuation percentiles are unavailable; individual stock anchors (2026-11-15) show extreme divergence — Dongcheng Pharma at 50x PE-TTM / 2.36x PB (23rd percentile over 10 years, priced as an innovative radiopharma option), China Isotope & Radiation at 0.59x PB (0th percentile over 10 years, historic low range; on an attributable-net-profit basis, 2025 net profit of RMB 327 million, -19.5%, PE needs re-rating on a market-cap basis to roughly 11-18x). The market is pricing deep skepticism about the sustainability of China's nuclear pharmacy networks' 70% segment gross margin — this is the industry's biggest pricing divergence.
Policy matrix (net direction): China = strong tailwind — the Medium- and Long-Term Development Plan for Medical Isotopes (2021-2035) and the Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026) set quantified self-sufficiency targets; State Council Decree No. 797 (effective January 2025) removed the licensing requirement for medical institutions to use Class I and Class II radiopharmaceuticals, lowering administration barriers; CDE clinical guidance for radiopharmaceuticals (2023/2024) completed review standards; the 2025 NRDL (National Reimbursement Drug List) added radionuclide diagnostic agents, and Pluvicto is a candidate for the next round of national price negotiations. US = tailwind on demand and regulation, neutral on supply — OPPS payment rule transparency, FDA radiopharmaceutical dose optimization guidance (August 2025 draft), NRC planning to reduce licensee burden; but the NNSA Mo-99 funding program is winding down (only SHINE remains), and the mandatory LEU conversion is complete, raising legacy capacity costs; IRA drug price negotiations will include Part B from the third round onward, though no radiopharmaceuticals appeared in the first three rounds' lists — a longer-term headwind for the 2030s. EU = neutral — the Critical Medicines Act does not cover isotopes; only Euratom monitoring applies. Headwind list (must not be selectively omitted): expansion of China's centralized procurement of nuclear medicine / DRG payment reform (equipment procurement has already driven this segment at China Isotope down -50.8%), US IRA Part B longer-term, and Russia-Ukraine sanctions potentially lifting the nuclear medicine exemption (OFAC GL 6D currently preserves Russian isotope transactions). Geopolitics: Russia's Rosatom exposure is real in c.a. Lu-177 (~30% share of formulated product) and stable isotope enrichment (Yb-176 target material); China's self-sufficiency push (Qinshan/Jiajiang/solution reactors) will mid-term depress the global Lu-177 price center and shift trade flows. On ESG, there are no direct carbon-constraint exposures; radiation safety licensing is a routine threshold.
D1 (the decisive battle): Mo-99 in 2027 — tight balance or structural oversupply? Bulls (for legacy producers): SHINE's operating license not yet approved, DOE loan not closed, NRC completion deadline pushed to late 2029, plus HFR/LVR-15 aging risks — 2027 is more likely to see a repeat shortage spike and legacy producer price hikes. Bears: once SHINE ships in 2027-2028, full capacity of 8,200 six-day Ci/week = 85% of global weekly demand; adding Chinese reactors and Darlington, nominal oversupply of 70%+ in 2028-2029, triggering price wars and early retirement of legacy reactors. Watch: NRC operating license approval, DOE loan closing, HFR/BR2 maintenance schedules, SHINE's first commercial order. D2: Lu-177 demand bridge delivery vs. supply expansion + generic erosion. mHSPC penetration is the biggest variable (this report's base case: 8%, range 5-12%); BRAVNETSA (Lutathera generic) 2027 pricing and ramp will determine NET-side volume-price dynamics; n.c.a. price center -10~-25%. Watch: Novartis' first-year mHSPC guidance, BRAVNETSA pricing, Chinese domestic Lu-177 listing prices, ITM Neufahrn/Bruce U7 ramp. D3: Duration of the Ac-225 scarcity premium window. Approval timing (RYZ101 filing / FPI-2265) × GMP capacity ramp (DOE allocation phase-out pace, TerraPower 2029) will determine whether the premium holds through 2029-2030 or fades early; nominal capacity at 8x demand is the sword of Damocles for 2030+. Watch: RYZ101 FDA acceptance, isotopes.gov allocation announcements, TerraPower/Niowave construction milestones.
Three scenarios (12-24 months):
| Scenario | Probability | Narrative | Implications |
|---|---|---|---|
| Bear | 25% | mHSPC penetration <6%, BRAVNETSA opens a NET generic price war; expansion of China's nuclear medicine centralized procurement; SHINE at full capacity on schedule + legacy reactors life-extended → full-blown Mo-99/Lu-177 price war, early fade of the Ac premium | Double derating of upstream raw materials and networks; profit concentrates further with branded players; avoid commodity APIs and high-valuation option-style names |
| Base | 55% | SHINE delayed, real shipments in 2028; Mo-99 tight in 2027, oversupplied 2028-2029 (+23%~+37%); Lu-177 delivery CAGR ~15%, n.c.a. price center -10~-25%; Ac-225 premium through 2029-2030; steady network growth | Branded closed loops + licensed networks + short-window scarce APIs outperform; legacy Mo-99 producers' profits remain stable through 2027 |
| Bull | 20% | Extended unplanned outages at legacy reactors (2024 repeat) + SHINE delayed to 2029 → Mo-99 shortage spike and price hikes; RLT beats expectations (penetration >12%, both Ac drugs approved on time) → volume-price rise in Lu/Ac; Chinese Lu-177 export premium | Scarce APIs and legacy reactor capacity holders benefit most (listed proxies: Cardinal generator margin improvement, Telix/ITM) |
The decision matrix logic: upper right (core allocation) is the Novartis-style branded closed loop — strongest demand momentum with the most thoroughly internalized profits; Telix/ITM sits in the upper right slightly lower (real but time-limited scarce API bargaining power); Cardinal/Grand Pharma in mid-right (steady network and product momentum, above-average returns); lower right is the value trap zone — Dongcheng Pharma (56,38) and second-tier RDC without isotope/network lock-in (55,15): industry volume growth is real, but a declining raw material price center + generic erosion + option-style pricing at 50x PE mean "industry momentum" cannot convert into shareholder returns; lower left (avoid) is pure commodity-grade Mo-99 capacity (declining momentum + commoditization); China Isotope falls near the midline slightly below (52,42) — the 70% nuclear pharmacy segment gross margin is real, but company-level ROE is ~3.5% with profits declining for two consecutive years; the low PB is fair pricing of low returns, not a mispricing; rated as watch (repair catalysts: A-share listing, centralized procurement exemption for nuclear medicine, volume ramp of new Lu/Ac products).
Beneficiaries (base scenario): ①Novartis (NVS) — RLT branded closed loop + four self-built plants internalizing API/synthesis/distribution profits; mHSPC opens a 3-4x patient population pool; ②Telix (TLX.AX) — post-ITM acquisition, holds globally dominant n.c.a. Lu-177 capacity and Ac-225 positioning; short-window scarce APIs + diagnostic imaging agent cash flows; ③Cardinal Health (CAH) — the largest US nuclear pharmacy network; Tc/PET diagnostic cash cows + RLT clinical trial distribution; note its limited therapeutic-side exposure; ④Grand Pharma (0512.HK) — Y-90 SIRT (new FDA liver cancer indication July 2025) + nuclear medicine segment +61% as a proxy for China volume growth. Avoid/caution: pure commodity-grade Mo-99 capacity (recommend deferring evaluation until SHINE's operating license is approved); second-tier RDC pipeline companies without isotope supply or network lock-in; Dongcheng Pharma (50x PE already prices in substantial innovation options; the fundamentals of FDG +18% / nuclear medicine +12% cannot support the valuation elasticity — interested names can be filed separately for target price analysis).
Scenarios × Names:
| Scenario | Biggest Beneficiaries | Biggest Losers |
|---|---|---|
| Bear (25%) | Novartis (passive profit share concentration); Cardinal, the cash-richest among licensed networks | Dongcheng Pharma, second-tier RDC (options falsified); Ac-225 new capacity investors |
| Base (55%) | Novartis, Telix/ITM (Ac window), Cardinal | New commodity Mo-99 entrants; IRE/Curium/NTP (unlisted, from 2028) |
| Bull (20%) | Telix/ITM (volume-price rise), Cardinal (generator margin improvement + shortage spike), legacy reactor capacity holders | Shorts betting on "2027 oversupply"; downstream buyers locking in high-priced Ac-225 long-term contracts |
Key Risks: ① SHINE timing — two-sided risk (delay → shortage spike / on schedule → premature price war); ② RLT penetration below expectations (mHSPC <6% scenario would cut 2030 Lu-177 demand by another 10-15%); ③ expansion of China's medical insurance centralized procurement pressuring radiopharmaceutical prices and network margins; ④ IRA Part B adding high-value radiopharmaceuticals in the 2030s; ⑤ Russia-Ukraine sanctions escalation lifting the nuclear medicine exemption, Yb-176 target material supply disruption; ⑥ unplanned legacy reactor outages (always a spike risk, 2024 precedent).
Note: This report uses a generic value chain framework. Per-isotope capacity, treatment courses, and prices are mostly inference layers based on company disclosures/institutional estimates, with sources noted in the text; there are no public price series for Mo-99/Lu-177, so price paths are indexed range judgments.